Toby Eyre
Consultant Haematologist
University of Oxford / Oxford University Hospitals · Oxford, United Kingdom
Rising UK MCL expert with influential real-world data publications on BTK inhibitor outcomes in MCL and focus on high-risk TP53-mutated disease.
A matching-adjusted indirect comparison of survival outcomes with pirtobrutinib (BRUIN) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma previously treated with a covalent Bruton tyrosine kinase inhibitor.
British journal of haematology · Jan 1, 2026
Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysis.
Current medical research and opinion · Dec 1, 2025
Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial.
Lancet (London, England) · Oct 25, 2025
EHA-EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma.
HemaSphere · Oct 1, 2025
Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase-Targeted Approaches.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · Jul 10, 2025
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial.
Haematologica · Jan 1, 2025
Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study.
Blood · Aug 29, 2024
Ibrutinib as first-line therapy for mantle cell lymphoma: a multicenter, real-world UK study.
Blood advances · Mar 12, 2024
Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience.
Blood advances · Feb 27, 2024
Complete response of mantle cell lymphoma with central nervous system involvement at diagnosis with acalabrutinib - Case report.
EJHaem · Feb 1, 2024
Diagnosis and management of mantle cell lymphoma: A British Society for Haematology Guideline.
British journal of haematology · Jan 1, 2024
Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma.
Leukemia & lymphoma · Jan 1, 2024